Study 451 showed a 4.8-point greater reduction in YMRS total score versus placebo and significant improvement from Day 3, while a second pivotal readout remains essential.
Key Takeaways
- Johnson & Johnson’s CAPLYTA (lumateperone) met the primary endpoint in the pivotal Phase 3 Study 451 in adults with bipolar I mania.
- CAPLYTA produced significant improvement from Day 3, with a 45.8% clinical response rate versus 20.9% for placebo.
- CAPLYTA is not approved for bipolar mania, and results from the completed second Phase 3 study remain critical to a potential label expansion.
Data Snapshot
| Item | Study 451 Result |
|---|---|
| Company | Johnson & Johnson |
| Product | CAPLYTA (lumateperone) |
| Trial | Phase 3 Study 451; NCT06462586 |
| Population | Adults with manic episodes, with or without mixed features, associated with bipolar I disorder |
| Treatment | CAPLYTA 42 mg orally once daily |
| Comparator | Placebo |
| Treatment period | Three weeks |
| Primary endpoint | Change in Young Mania Rating Scale (YMRS) total score |
| Placebo-adjusted difference | 4.8-point greater reduction |
| Effect size | −0.69 |
| Statistical result | p<0.0001 |
| Onset of significant improvement | Day 3 |
| Clinical response at Week 3 | 45.8% vs. 20.9% |
| Key secondary result | CGI-S least-squares mean difference of −0.5; p<0.0001 |
| Common treatment-related adverse events | Dry mouth: 7.9% vs. 3.4%; nausea: 7.9% vs. 2.3% |
| Bipolar-mania status | Not FDA approved |
| Next catalyst | Phase 3 Study 452 results |
What Happened
Johnson & Johnson reported positive results from Study 451, the first of two pivotal Phase 3 trials evaluating CAPLYTA in adults with manic episodes associated with bipolar I disorder.
The randomized, double-blind study compared CAPLYTA 42 mg once daily with placebo for three weeks. CAPLYTA produced a 4.8-point greater reduction in the Young Mania Rating Scale (YMRS) total score at Week 3, meeting the primary endpoint. Significant improvement was observed from Day 3 and sustained through Week 3.
Clinical response—defined as at least a 50% reduction in the YMRS total score—was achieved by 45.8% of CAPLYTA-treated patients versus 20.9% of placebo-treated patients. CAPLYTA also improved the Clinical Global Impression–Severity (CGI-S) score, with a least-squares mean difference of −0.5 versus placebo.
The most common treatment-related adverse events occurring in at least 5% of patients and at twice the placebo rate were dry mouth and nausea, both reported in 7.9% of CAPLYTA-treated patients. Johnson & Johnson reported low discontinuation rates and a safety profile consistent with CAPLYTA’s established profile. (Johnson & Johnson Phase 3 results)
Fierce Pharma described Study 451 as the first of two Phase 3 studies evaluating CAPLYTA in bipolar mania. The second pivotal trial, Study 452, has been completed, but its results remain under analysis. (Fierce Pharma)
Why It Matters
CAPLYTA is an oral, once-daily atypical antipsychotic currently approved in the United States for schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and adjunctive treatment of major depressive disorder.
CAPLYTA is not approved for manic episodes.
A bipolar-mania approval could allow Johnson & Johnson to position CAPLYTA across both depressive and acute manic episodes associated with bipolar I disorder. This would place the drug in more direct competition with treatments such as VRAYLAR (cariprazine), which is already approved for both bipolar depression and acute manic or mixed episodes.
However, Study 451 remains one pivotal study. The regulatory outlook will depend heavily on whether Study 452 reproduces the efficacy signal and maintains a consistent safety profile.
The publicly available evidence also remains limited to company-reported results and a conference presentation. Full study data will be needed to assess subgroup consistency, discontinuations and the broader safety profile.
The Science Behind CAPLYTA
Want the receptor-level explanation? Read my BP Science analysis: CAPLYTA Mechanism in Bipolar Mania: Dual D2 Modulation.
CAPLYTA’s Competitive Position in Bipolar Mania
| Company | Product | U.S. status | Clinical and dosing characteristics | Market position |
|---|---|---|---|---|
| Johnson & Johnson | CAPLYTA (lumateperone) | Study 451 positive; not approved for mania | Oral 42 mg once daily; improvement from Day 3; Study 452 results pending | Potential expansion from bipolar depression into acute mania |
| AbbVie / Gedeon Richter | VRAYLAR (cariprazine) | FDA approved in 2015 | Oral once daily; 3–6 mg for adult mania; akathisia and extrapyramidal symptoms are important considerations | Closest branded competitor with both bipolar-depression and mania indications |
| AstraZeneca / generics | SEROQUEL (quetiapine) | FDA approved in 2004 | Immediate-release and extended-release formulations; sedation and metabolic effects can limit use | Established bipolar treatment with broad generic availability |
| Eli Lilly / generics | ZYPREXA (olanzapine) | FDA approved in 2000 | Oral once daily; intramuscular option available; substantial weight and metabolic burden | Established high-efficacy generic option |
| Otsuka / Bristol Myers Squibb / generics | ABILIFY (aripiprazole) | FDA approved in 2004 | Oral once daily; akathisia and activation can occur; long-acting formulations available for maintenance | Widely used generic option with multiple formulations |
| Johnson & Johnson / generics | RISPERDAL (risperidone) | FDA approved in 2003 | Oral once or twice daily; prolactin elevation and extrapyramidal symptoms are relevant limitations | Established and inexpensive acute-mania treatment |
| Alkermes | LYBALVI (olanzapine/samidorphan) | FDA approved in 2021 | Oral once daily; contraindicated with opioid use; metabolic monitoring remains necessary | Branded olanzapine-based option differentiated by its weight-gain mitigation strategy |
The approval dates and clinical characteristics are based on U.S. Food and Drug Administration reviews and current prescribing information. (FDA VRAYLAR review, FDA SEROQUEL review, FDA-approved bipolar treatments, DailyMed LYBALVI label)
Lithium and valproate also remain established treatments for acute mania, although their use involves therapeutic monitoring and distinct renal, hepatic, metabolic or reproductive safety considerations.
CAPLYTA has not been compared directly with these treatments in a head-to-head bipolar-mania trial. Efficacy and adverse-event rates from separate studies should therefore not be interpreted as direct comparative evidence.
BP View
Study 451 gives Johnson & Johnson a credible first pivotal result in bipolar mania. The 4.8-point placebo-adjusted YMRS difference, improvement from Day 3 and more than twofold difference in clinical response collectively support a meaningful efficacy signal.
The commercial opportunity is broader than adding another indication. A bipolar-mania approval could extend CAPLYTA from depressive episodes into the acute manic phase of bipolar I disorder, strengthening its position within Johnson & Johnson’s neuroscience portfolio.
The challenge is differentiation. Bipolar mania already has several effective and inexpensive generic treatments, while VRAYLAR provides the clearest branded precedent across both manic and depressive episodes. CAPLYTA will need to compete through its overall balance of efficacy, tolerability and once-daily administration.
Study 452 is therefore the next decisive catalyst. A consistent second result would substantially strengthen the regulatory case, while an inconsistent result would limit the value of the positive Study 451 readout.
Related Post
For another recent neuroscience program in which a second pivotal study is central to the regulatory outlook, read my previous analysis: FDA Pauses Opakalim Enrollment Days After SK Biopharmaceuticals Deal.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Leave a Reply